Post-exposure treatment with isoproterenol attenuates pulmonary edema in phosgene-exposed rabbits

Journal of Applied Toxicology

Volumn 18, Issue 5, 1998, Pages 321-329

  Sciuto, Alfred M ^a,d   Strickland, Paul T ^b   Gurtner, Gail H ^c  

^a U States Army Med Res Inst C   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Intratracheal treatment; Intravascular treatment; Isoproterenol; Phosgene; Protective mechanism

Indexed keywords

CYCLIC AMP; GLUTATHIONE; ISOPRENALINE; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LIQUID NITROGEN; PHOSGENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY PERMEABILITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; INTRAARTERIAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; ISOLATED LUNG; LUNG ARTERY PRESSURE; LUNG CAPILLARY; LUNG EDEMA; LUNG PERFUSION; LUNG WEIGHT; MALE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RABBIT; TRACHEA PRESSURE;

ANIMALS; CYCLIC AMP; GLUTATHIONE; ISOPROTERENOL; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LUNG; MALE; PHOSGENE; PULMONARY EDEMA; RABBITS; TIME FACTORS;

EID: 0031692190     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1263(1998090)18:5<321::AID-JAT516>3.0.CO;2-4     Document Type: Article

References (48)

1. NIOSH, Criteria for a Recommended Standard: Occupational Exposure to Phosgene, USDEW, PHS, CDC publication no. 76137. NIOSH, Washington, DC (1976).
2. W. F. Diller, Medical phosgene problems and their possible solutions. J. Occup. Med. 20(3), 189-193 (1978).
3. J. M. Tobias, The pathological physiology of the lung after phosgene. In Fasciulus on Chemical Warfare Medicine, Vol. II, p. 331. National Research Council Committee on Treatment of Gas Casualties, Washington, DC (1945).
4. E. R. Trethewie, Pharmacology of phosgene. Med. J. Austr. 20, 612-618 (1947).
5. I. Daly de Burgh, P. Eggleton, S. R. Elsden and C. O. Hebb, Biochemical study of isolated perfused lungs with special reference to the effects of phosgene. Q. J. Exp. Physiol. 33, 215-240 (1946).
6. W. F. Diller and R. Zante, Dosis-Wirkungs-Beziehungen bei Phosgeneinwirkung auf Mensch und Tier. Zentralbl. Arbeitsmed. Arbeitsschutz Prophyl. Ergon. 32, 360-368 (1982).
7. W. F. Diller, J. Bruch and W. Dehnen, Pulmonary changes in the rat following low phosgene exposures. Arch. Toxicol. 57, 184-190 (1985).
8. E. Laqueur and R. Magnus, Über Kampfgasvergiftungen: III. Experimentelle Pathologie der Phosgenvergiftung. Zs. Gesamte Exp. Med. 13, 200-290 (1921).
9. A. M. Potts, F. P. Simon and R. W. Gerard, The mechanism of phosgene and diphosgene. Arch. Biochem. 24, 329-337 (1949).
10. H. Babad and A. G. Zeiler, The chemistry of phosgene. Chem. Rev. 73(1), 75-91 (1973).
11. R. Pawlowski and M. F. Frosolono, Effects of phosgene on rat lungs after a single high-level exposure. II. Ultrastructural alterations. Arch. Environ. Health 32, 278-283 (1977).
12. W. D. Currie, G. E. Hatch and M. F. Frosolono, Pulmonary alterations in rats due to phosgene inhalation. Fundam. Appl. Toxicol. 8, 107-114 (1987).
13. M. F. Frosolono and R. Pawlowski, Effect of phosgene on rat lungs after single high-level exposure: I. Biochemical alterations. Arch. Environ. Health 32, 271-277 (1977).
14. W. D. Currie, G. E. Hatch and M. F. Frosolono, Changes in lung ATP concentration in the rat after low-level phosgene exposure. J. Biochem. Toxicol. 2, 105-114 (1987).
15. Y-L. Guo, T. P. Kennedy, J. R. Michael, A. M. Sciuto, A. Ghio, N. F. Adkinson and G. H. Gurtner, Mechanisms of phosgene-induced toxicity: role of arachidonate mediators. J. Appl. Physiol. 69(5), 1615-1622 (1990).
16. T. P. Kennedy, J. R. Michael, J. R. Hoidal, D. Hasty, A. M. Sciuto, C. Hopkins, R. Lazar, G. K. Bysani, E. Tolley and G. H. Gurtner, Dibutyryl cAMP, aminophylline, and beta adrenergic agonist protect against pulmonary edema caused by phosgene. J. Appl. Physiol. 67(6), 2542-2552 (1989).
17. A. M. Sciuto, P. T. Strickland, T. P. Kennedy, Y-L. Guo and G. H. Gurtner, Intratracheal administration of DbcAMP attenuates edema formation in phosgene-induced acute lung injury. J. Appl. Physiol. 80(1), 149-157 (1996).
18. A. M. Sciuto, R. R. Stotts, V. Chittenden, E. Choung and M. Heflin, Spectrophotometric changes in absorbance at 412-415 nm in plasma from three rodent species exposed to phosgene. Biochem. Biophys. Res. Commun. 226, 906-911 (1996).
19. A. M. Sciuto, P. T. Strickland, T. P. Kennedy and G. H. Gurtner, Postexposure treatment with aminophylline protects against phosgene-induced acute lung injury. Exp. Lung Res. 23, 317-332 (1997).
20. N. R. Mettler, M. E. Gray, S. Schuffman and V. A. LeQuire, β-Adrenergic induced synthesis and secretion of phosphatidyl-choline by isolated pulmonary alveolar type II cells. Lab. Invest. 45, 575-586 (1981).
21. G. M. Rubanyi and F. Vanhoutte, Endothelium removal decreases relaxation of canine coronary arteries caused by beta-adrenergic agonist and adenosine. J. Cardiovasc. Pharmacol. 7, 139-144 (1985).
22. L. Birnbaumer and R. Iyengar, Coupling of receptors to adenylate cyclase. In Handbook of Experimental Pharmacology, Vol. 58 (I), Chapt. 3, ed. by J. A. Nathanson and J. W. Kebabian. Springer Verlag, Berlin (1982).
23. T. R. Gelzleichter, H. Witschi and J. A. Last, Concentration-response relationships of rat lung to exposure to oxidant air pollutants: a critical test of Haber's Law for ozone and nitrogen dioxide. Toxicol. Appl. Pharmacol. 112, 73-80 (1992).
24. W. E. Rhinehart and T. Hatch, Concentration-time product (CT) as an expression of dose in sublethal exposures to phosgene. Am. Ind. Hyg. Assoc. J. 25, 545-553 (1964).
25. I. Farrukh, J. R. Michael, W. R. Summer, N. F. Adkinson and G. H. Gurtner, Thromboxane-induced pulmonary vaso-constriction: involvement of calcium. J. Appl. Physiol. 58(1), 33-44 (1985).
26. E. C. Hayes, D. Lombarde, Y. Girard, J. Maycock, A. Rokach, R. Rosenthal, R. Young, W. Egan and H. Sweerink, Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J. Immunol. 131, 429-433 (1983).
27. S. Peters, E. Schulman, M. Liu, E. Hayes and L. Lichtenstein, Separation of major prostaglandins, leukotrienes, and monoHETEs by high performance liquid chromatography. J. Immunol. 64, 335-343 (1983).
28. F. Tietze, Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal. Biochem. 27, 502-522 (1969).
29. M. E. Akerboom and H. Sies, Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol. 77, 373-382 (1981).
30. O. Lowry, N. J. Roesbrough, A. L. Farr and R. J. Randall, Protein measurement with folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
31. D. B. Duncan, Multiple range tests for correlated and heteroscedastic means. Biometrics 13(2), 164-176 (1957).
32. I. S. Farrukh, G. H. Gurtner and J. R. Michael, Pharmacological modification of pulmonary vascular injury: possible role of cAMP. J. Appl. Physiol. 62(1), 47-54 (1987).
33. T. Foy, J. Marion, K. Brigham and T. R. Harris, Isoproterenol and aminophylline reduce lung capillary filtration during high permeability. J. Appl. Physiol.: Respir. Environ. Ex. Physiol. 46(1), 146-151 (1979).
34. F. L. Minnear, A. Johnson and A. S. Malik, Beta-adrenergic modulation of pulmonary transvascular fluid and protein exchange. J. Appl. Physiol. 60(1), 266-274 (1986).
35. I. Mizus, W. Summer, I. Farrukh, J. R. Michael and G. H. Gurtner, Isoproterenol or aminophylline attenuate pulmonary edema after acid injury. Am. Rev. Respir. Dis. 131, 256-259 (1985).
36. C. G. A. Persson, M. Ekman and I. Erjefalt, Vascular antipermeability effects of beta-receptor agonists and theophylline in the lung. Acta Pharmacol. Toxicol. 44, 216-220 (1979).
37. M. E. Duffey, B. Hainau, S. Ho and C. Bentzel, Regulation of tight junction epithelial junction permeability by cyclic AMP. Nature 294, 451-453 (1981).
38. D. Shasby, S. S. Shasby, J. M. Sullivan and M. J. Peach, Role of endothelial cell cytoskeleton in control of endothelial permeability. Circ. Res. 51, 657-661 (1982).
39. R. J. Werrlein, S.D. Kirby and J. Madren-Whalley, Phosgene-induced calcium changes in pulmonary artery endothelial cells. In Advances in Animal Testing for Safety and Efficacy, ed. by H. Salem and S. Katz, Taylor and Francis, Washington, DC (1997).
40. 2+ in beta-adrenergic relaxation of a smooth muscle. Nature 281, 682-683 (1979).
41. 45Ca fluxes in isolated smooth muscle cells. Am. J. Physiol. 246, C431-438 (1984).
42. I. Parker, Y. Ito, H. Kuriyama and R. Miledi, β-Adrenergic agonists and cyclic AMP decrease intracellular resting free-calcium concentration in ileum smooth muscle. Proc. R. Soc. London, Ser. B 230, 207-214 (1987).
43. K. D. Meisheri and C. van Breeman, Effects of beta-adrenergic stimulation on calcium movements in rabbit aortic smooth muscle: relationship with cAMP. J. Physiol. 331, 429-441 (1982).
44. D. J. Fawthrop, A. R. Boobis and D. S. Davies, Mechanisms of cell death. Arch. Toxicol. 65, 437-444 (1991).
45. ++ by liver mitochondria. J. Biol. Chem. 259(2), 1279-1287 (1984).
46. A. Gillissen, M. Jaworska, B. Schärling, D. van Zwoll and G. Schultze-Werninghaus, Beta-2-agonists have antioxidant function in vitro. 1. Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid, and hydroxyl radical. Respiration 64, 16-22 (1997).
47. L. A. S. Brown and W. J. Longmore, Adrenergic and cholinergic regulation of lung surfactant secretion in the isolated perfused rat lung and alveolar Type II cells in culture. J. Biol. Chem. 256, 66-72 (1981).
48. J. B. Warren, A. J. Wilson, R. K. Loi and M. L. Coughlan, Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J. 7, 1394-1400 (1993).